Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals board and management
25 filed, newest first.
May 2026
29 May · Management
Jun 2025
May 2025
Apr 2025
Feb 2025
14 Feb · Management
May 2023
19 May · Management
Feb 2023
Apr 2022
Oct 2020
Mar 2019
Nov 2017
Feb 2017
Oct 2016
May 2016
Oct 2015
May 2015
Nov 2014
Jan 2012
May 2011
10 May · Management
Board of Directors of the Company at their meeting held on May 10, 2011 has announced the following changes to the Board effective from May 10, 2011: (1) Mr. Gracias Saldanha, Chairman has stepped down as the Chairman of the Board of Directors and has been re-designated as Founder & Chairman Emeritus; (2) Mr. Glenn Saldanha has been appointed as the Chairman of the Board in addition to his responsibilities as MD of the Company; (3) Mr. A. S. Mohanty ceases to be a director of the Company.
Feb 2010
2 Feb · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Mr. M. Gopal Krishnan, Director; has resigned from the Board of Company with effect from January 29, 2010
Oct 2009
29 Oct · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated October 29, 2009 that "At the board meeting held today, Mr. Hocine Sidi Said, has been appointed as Additional Director of the Company. Mr. Hocine Sidi Said is the Founder & Director of Bio-nAbler, an investment company that partners with Sovereign Wealth Funds and Private Equity Firms across Asia and the MENA region to identify and execute product and company acquisitions. Mr. Said has over 20 years of experience in the pharmaceutical industry and has worked with companies like Pfizer and UCB. During his stint at UCB, he was incharge of the entire Emerging Markets Region and designated as Senior Vice President".
Aug 2009
20 Aug · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the meeting of the Board of Directors held on August 14, 2009, Mr. D. R. Mehta has been appointed as Additional Director of the Company. Mr. D. R. Mehta is a Graduate in Arts & Law from the Rajasthan University. He also studied at Royal Institute of Public Administration, London U.K and Alfred Sloan School of Management, MIT, Boston, USA. Mr. Mehta has been a civil servant for almost four decades and has extensive and diverse experience of administration and management of public affairs. He joined the Indian Administrative Service in 1961 and has held numerous important positions in the Government of Rajasthan and later in the Government of India. He has served as the Deputy Governor of the Reserve Bank of India and as the Chairman of the Securities and Exchange Board of India. Further, at the same meeting, Mrs. B. F. Saldanha has also been appointed as Additional Director of the Company.
Apr 2009
15 Apr · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "In line with the requirements of Clause 49 I (A) of the listing agreement relating to the composition of the Board, the Board of Directors has been reconstituted. As part of the reconstitution, Mr. R. V. Desai Director-Finance & Legal and Mrs. B. E. Saldanha Director have resigned from the board effective April 01, 2009. Mr. R.V. Desai continues as CFO of the Company effective April 01, 2009".
Feb 2009
26 Feb · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Mr. M. J. Mendonza, has joined the Company as Vice President-Legal & Company Secretary with effect from February 06, 2009.